We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva stock fell early Wednesday after the pharma giant reported adjusted earnings of 71 cents per share on $4.23 billion in ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

SaverOne 2014 (SVRE) announced the award of a new contract with Teva Pharmaceutical (TEVA), to install the SaverOne System across its entire ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...